CARM1 and neoplasm: The critical histone modifying component of NUMAC, CARM1, has been proposed as a cancer target and its knockdown enhances antigen-induced proliferation and cytotoxicity in tumor-infiltrating T-cells50, which is also observed in ibrutinib-treated patients52,53.